Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E16.99 EPS (ttm)5.25 Insider Own0.20% Shs Outstand769.60M Perf Week-2.15%
Market Cap68.60B Forward P/E8.78 EPS next Y10.16 Insider Trans-2.40% Shs Float749.78M Perf Month4.90%
Income4.21B PEG0.87 EPS next Q1.96 Inst Own80.60% Short Float2.09% Perf Quarter-14.74%
Sales13.00B P/S5.28 EPS this Y109.10% Inst Trans0.46% Short Ratio2.12 Perf Half Y-26.53%
Book/sh8.95 P/B9.96 EPS next Y20.09% ROA9.70% Target Price115.62 Perf Year-27.62%
Cash/sh15.65 P/C5.70 EPS next 5Y19.57% ROE35.80% 52W Range84.25 - 147.17 Perf YTD-14.58%
Dividend- P/FCF13.81 EPS past 5Y25.80% ROI29.40% 52W High-39.43% Beta1.48
Dividend %- Quick Ratio4.80 Sales past 5Y18.70% Gross Margin96.50% 52W Low5.80% ATR2.29
Employees7467 Current Ratio5.00 Sales Q/Q16.90% Oper. Margin35.90% RSI (14)47.37 Volatility2.01% 2.80%
OptionableYes Debt/Eq1.24 EPS Q/Q187.20% Profit Margin22.60% Rel Volume0.52 Prev Close89.49
ShortableYes LT Debt/Eq1.24 EarningsMay 04 BMO Payout0.00% Avg Volume7.39M Price89.14
Recom2.20 SMA200.40% SMA50-1.28% SMA200-21.03% Volume3,879,889 Change-0.39%
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
Oct-23-17Resumed Piper Jaffray Neutral $133
Oct-20-17Reiterated UBS Buy $153 → $146
Oct-20-17Downgrade Robert W. Baird Outperform → Neutral $162 → $136
Apr-24-18 04:56PM  U.S. Supreme Court upholds legality of patent review process Reuters
10:10AM  U.S. Supreme Court upholds legality of patent review process Reuters
07:30AM  New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting Business Wire
06:01AM  Better Buy: Amgen Inc. vs. Celgene Motley Fool
Apr-23-18 05:00PM  CELG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018 GlobeNewswire
04:57PM  After headline drug flops in trials, Peninsula biotech sheds 70% of its value American City Business Journals
06:00AM  Biotech Stocks Face a Steep Drop Investopedia
Apr-22-18 07:15AM  2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line Motley Fool
Apr-20-18 10:50PM  CELGENE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG Business Wire
03:30PM  EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 CELG Business Wire
10:08AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
Apr-19-18 05:51PM  Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm Business Wire
04:30PM  MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble Yahoo Finance Video
03:43PM  Top Research Reports for IBM, McDonald's & Gilead Zacks
07:48AM  Celgene Corporation Announces Changes to Its Board of Directors Business Wire
04:27AM  Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising Moody's
Apr-18-18 02:00PM  Why Big Biotech Stocks May Get An Earnings Boost Investopedia
12:33PM  Big Biotech ETF Can Bounce Back ETF Trends
Apr-17-18 07:35AM  New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
06:32AM  Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets Motley Fool
Apr-16-18 03:09PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 CELG GlobeNewswire
01:40PM  MARKETS: These are the top risks CEOs are citing this earnings season Yahoo Finance Video
Apr-15-18 01:17PM  Is bluebird bio, Inc. a Buy on the Dip? Motley Fool
Apr-13-18 10:50PM  CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG GlobeNewswire
08:18AM  These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years Motley Fool
Apr-12-18 09:00PM  Wait for a Pullback Before Rolling the Dice on SPPI Stock InvestorPlace
05:51PM  U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report TheStreet.com
02:49PM  The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation Business Wire
06:00AM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Apr-11-18 11:40AM  This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous Motley Fool
Apr-10-18 02:05PM  MARKETS: Welcome to the low volume, low liquidity algo-driven market Yahoo Finance Video
11:23AM  Agios Pharmaceuticals Shares Rise on Buyout Speculation Zacks
Apr-09-18 04:15PM  The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation (CELG) Business Wire
02:34PM  CELGENE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Celgene Corporation to Contact The Firm ACCESSWIRE
02:22PM  Teva Chairman Says Tariffs Won't Have a Major Impact on Biotech Bloomberg Video
10:15AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 ACCESSWIRE
07:30AM  Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018 Business Wire
06:46AM  Novartis bets big on gene therapy with $8.7 billion AveXis deal Reuters
Apr-08-18 08:56AM  Biotech Fire Sale: 2 Top Stocks to Buy Next Week Motley Fool
06:16AM  3 Growth Stocks to Buy and Hold for 25 Years Motley Fool
Apr-07-18 10:01PM  [$$] Celgene hunts deals to offset loss of Revlimid patent protection Financial Times
12:40PM  Top 3 Healthcare Stocks for 2018 Investopedia
Apr-06-18 10:50PM  CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG PR Newswire
04:30PM  Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action and to the Abrupt Departure of Celgenes President GlobeNewswire
07:30AM  CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation Investors Business Wire
Apr-05-18 06:00PM  CELG INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation Business Wire
02:02PM  Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm PR Newswire
10:30AM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of Celgene Corporation Investors (CELG) Business Wire
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool
04:40PM  CELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation Investors Business Wire
04:21PM  Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier Investor's Business Daily
03:15PM  3 Growth Stocks at Deep-Value Prices Motley Fool
02:34PM  CELG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation Business Wire
11:08AM  Top 5 Biotech Stocks for 2018 Investopedia
08:10AM  Todays Research Reports on Stocks to Watch: Celgene and Pfizer ACCESSWIRE
Apr-03-18 11:49PM  [$$] Investors smart at ailing pharma deals Financial Times
08:03PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Celgene Corporation Investors (CELG) Business Wire
04:45PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation Business Wire
04:24PM  CELGENE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Celgene Corporation To Contact The Firm PR Newswire
11:05AM  Celgene (CELG) President and COO to Step Down: What's Ahead? Zacks
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 GlobeNewswire
09:23AM  Stocks to Watch: Spotify, Amazon, Apple, Tesla, GM, Intel, Disney, Longfin, Celgene, Overstock.com The Wall Street Journal
06:34AM  2 Big Biotech Bargains You Can Buy Now Motley Fool
Apr-02-18 06:25PM  Celgene shares tick lower as operating chief leaves MarketWatch
05:50PM  Celgene Chief Operating Officer Scott Smith abruptly resigns Reuters
05:44PM  Celgene Executive Responsible For Otezla Launch Exits Unexpectedly Investor's Business Daily
04:31PM  Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith Business Wire
03:57PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation Business Wire
02:53PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq: CELG) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
Mar-30-18 10:50PM  CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG GlobeNewswire
01:35PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm Business Wire
10:15AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 PR Newswire
07:30AM  Is Celgene a Beaten-Up Biotech Stock to Buy? Motley Fool
07:00AM  Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool
Mar-29-18 10:00PM  Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Celgene Corporation Business Wire
06:41PM  Geron Corp. Skyrocketed and AbbVie Inc. Crashed -- Are These Stocks Buys? Motley Fool
02:28PM  AbbVie Has a Growing Credibility Problem Bloomberg
11:00AM  Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate Zacks
08:45AM  Incyte Could Have a Problem (or 2!) on Its Hands Motley Fool
Mar-28-18 04:08PM  Celgene, Bluebird Team Up To Commercialize Multiple Myeloma Drug Investor's Business Daily
01:09PM  Celgene Shares Higher on Co-Development Pact With Bluebird TheStreet.com
10:50AM  Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio? Zacks
08:19AM  Bluebird bio's stock surges after Celgene co-development and promotion agreement MarketWatch
Mar-27-18 07:15PM  Is Gilead Sciences a Beaten-Up Biotech Stock to Buy? Motley Fool
06:13AM  4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End Zacks
Mar-26-18 04:17PM  Celgene Rises On Potential It Could Settle Over Generic Revlimid Investor's Business Daily
01:39PM  MARKETS: The S&P 500 just opened the strongest since right after Lehman failedwhich is telling Yahoo Finance Video
11:00AM  This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy Motley Fool
09:40AM  Celgene shares rise on expectation of Revlimid patent settlement MarketWatch
Mar-23-18 06:00PM  Arena Pharmaceuticals Takes Aim at Celgene Motley Fool
03:40PM  Will This Coming IPO Biotech Undercut Gilead, Novartis In Cancer Drugs? Investor's Business Daily
10:21AM  4 Top Stocks on My Buy Radar During This Correction Motley Fool
Mar-22-18 03:08PM  A $158 Billion Drug Giant Faces an Identity Crisis Bloomberg
10:42AM  Celgene Showing a Bullish Divergence But Is Still In a Downtrend TheStreet.com
08:33AM  Better Buy: Celgene Corporation vs. Biogen Inc. Motley Fool
Mar-21-18 05:41PM  Why Prothena Corp plc Shot 14.4% Higher Today Motley Fool
04:19PM  Prothena Rockets On Celgene Tie-Up In Neurological Diseases Investor's Business Daily
01:06PM  NYSE trader: Facebook is too big to fail, so I'm sticking with tech stocks Yahoo Finance Video
12:37PM  JP Morgan says this stock is too compelling to ignore CNBC Videos
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM